Related Experiment Video
Updated: Jun 30, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Role of rituximab therapy in glomerulonephritis
1Renal Medicine, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. dj106@cam.ac.uk
Abstract:
B cell depletion with the monoclonal antibody rituximab is attracting increasing attention in systemic lupus erythematosus, vasculitis, and primary glomerulonephritis. Existing, uncontrolled data report high response rates in patients with refractory disease. If supported by the results of ongoing randomized trials, then rituximab and related B cell-depleting or -modulating drugs are likely to become a component in the future management of these disorders. Their use may improve patient outcomes by permitting more complete disease control and reduced exposure to glucocorticoid and traditional immunosuppressive drugs. The toxicity and infective risk of B cell-targeted agents in renal disease needs to be determined as well as their optimal dosing in combination with conventional agents.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Respiratory Syncytial Virus Disease
Continuous Renal Replacement Therapy
Nephrotic Syndrome II : Assessment and Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
